Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm

This article was originally published in The Tan Sheet

Executive Summary

The developing Rx-to-nonprescription switch paradigm should exclude asthma and anaphylaxis drugs, advocates argue in a citizen petition. They say making inhalers available OTC contradicts the current standard for care.

You may also be interested in...



Primatene Firm Expects Approval, Counts On Brand Equity, Target Market

Amphastar Pharmaceuticals expects FDA to approve an amended NDA for Primatene HFA in 2016. Executives with the firm say sales of breath-triggered Primatene HFA could exceed annual revenues from the original Primatene Mist metered-dose inhaler before it was pulled from the market in 2011.

Primatene Firm Expects Approval, Counts On Brand Equity, Target Market

Amphastar Pharmaceuticals expects FDA to approve an amended NDA for Primatene HFA in 2016. Executives with the firm say sales of breath-triggered Primatene HFA could exceed annual revenues from the original Primatene Mist metered-dose inhaler before it was pulled from the market in 2011.

FDA’s Broad Power Can Overcome NSURE Labeling Obstacles – Attorney

Attorney Richard Kingham says the agency has authority to require broadly defined labeling for Rx-to-OTC switches, as well as to obligate generics to follow the same measures as innovator products. Consultant George Quesnelle says FDA’s openness to novel switch strategies on a case-by-case basis is key.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106465

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel